Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Withdrawn 1Unknown 1Completed 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 26Breast 3Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 3Neoplasm Metastasis 1

Interventions

Trastuzumab 347Paclitaxel 309Cyclophosphamide 286Docetaxel 267Carboplatin 215Capecitabine 214Letrozole 185Fulvestrant 176Doxorubicin 166Bevacizumab 136Anastrozole 120Tamoxifen 117pertuzumab 112pembrolizumab 112Epirubicin 110exemestane 107Vinorelbine 106Gemcitabine 106Albumin-Bound Paclitaxel 92Lapatinib 84130-nm albumin-bound paclitaxel 83Radiotherapy 79palbociclib 75eribulin 73Cisplatin 69pyrotinib 65Taxes 65Everolimus 55Goserelin 50Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Estramustine × Breast × Clear all
NCT02866955 2020-03-09

EFESE

Institut de Cancérologie de Lorraine

Phase 2 Completed
100 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02853071 2019-11-18

BEST

Centre Hospitalier Universitaire de Besancon

Phase 2 Withdrawn
Breast

Breast Neoplasms

NCT00003066 2014-01-06

Docetaxel Combined With Estramustine in Treating Women With Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
40 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡